Emerging Immunotherapies for Non-Hodgkin Lymphomas: The Tortoise Approaches the Finish Line
Authors: Oliver W. Press
Journal: Annals of Internal Medicine (2000)

Editorials6 June 2000Emerging Immunotherapies for Non-Hodgkin Lymphomas: The Tortoise Approaches the Finish LineOliver W. Press, MD, PhDOliver W. Press, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-11-200006060-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Disseminated malignancies continue to pose vexing problems for both patients and health care providers. Although localized malignant lesions can often be extirpated with surgery or radiation therapy, most metastatic neoplasms are difficult to cure despite systemic chemotherapy. Furthermore, the alopecia, nausea, myelosuppression, neurotoxicity, and nephrotoxicity that often accompany conventional chemotherapy are potent deterrents for many patients. Consequently, investigators and patients with cancer have long sought alternative therapies that might be effective while avoiding the dreaded side effects of chemotherapy. Immunologic interventions have been particularly appealing because they use “natural” components of the immune system to selectively eradicate malignant cells while ...References1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-7. CrossrefMedlineGoogle Scholar2. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab A, et al . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-45. CrossrefMedlineGoogle Scholar3. Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, et al . Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980;40:3147-54. MedlineGoogle Scholar4. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517-22. CrossrefMedlineGoogle Scholar5. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood. 1998;92:1184-90. CrossrefMedlineGoogle Scholar6. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al . Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584-91. CrossrefMedlineGoogle Scholar7. Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns , et al . IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-74. CrossrefMedlineGoogle Scholar8. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-33. CrossrefMedlineGoogle Scholar9. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al . Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-32. MedlineGoogle Scholar10. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al . Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-76. CrossrefMedlineGoogle Scholar11. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al . Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-81. CrossrefMedlineGoogle Scholar12. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al . Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2(3):457-70. Google Scholar13. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al . Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-803. CrossrefMedlineGoogle Scholar14. Kaminski MS, Gribbin T, Estes J, Ross CW, Regan D, Zasadny K, et al . I-131 anti-B1 antibody for previously untreated follicular lymphoma: clinical and molecular remissions [Abstract]. Proc Am Soc Clin Oncol. 1998;17:2a. Google Scholar15. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al . Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-24. CrossrefMedlineGoogle Scholar16. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al . Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-40. CrossrefMedlineGoogle Scholar17. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, et al . Follow-up of relapsed B cell lymphoma patients treated with I-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270-8. CrossrefMedlineGoogle Scholar18. DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, et al . Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-56. CrossrefMedlineGoogle Scholar19. Juweid M, Sharkey RM, Marlowitz A, Behr T, Swayne LC, Dunn R, et al . Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 1995;55:5899-907. Google Scholar20. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al . Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86:4063-75. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Grant Support: By grants CA55596 and CA76287 from the National Institutes of Health.Corresponding Author: Oliver W. Press, MD, PhD, Division of Oncology, EE-122, Department of Medicine, University of Washington Medical Center, Box 356043, Seattle, WA 98195-6043; e-mail, [email protected]washington.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin LymphomaRadioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodiesA model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortionHighlights From: 37th Annual American Society of Clinical Oncology Meeting, San Francisco, CA May 12–15, 2001 6 June 2000Volume 132, Issue 11Page: 916-918KeywordsAntibodiesAntibody therapyAntigensB cellsCellsChemotherapyLymphocytesLymphomaMonoclonal antibodiesTransplantation Issue Published: 6 June 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...